Most recent by Angela DeMichele, MD, MSCE
Sacituzumab govitecan effective for triple-negative breast cancer regardless of biomarkers
Women with metastatic triple-negative breast cancer benefited from sacituzumab govitecan irrespective of their Trop-2 expression level and BRCA1/BRCA2 mutation status, according to data from the phase 3 ASCENT study.
Adjuvant palbociclib fails to improve invasive DFS in high-risk breast cancer
The addition of 1 year of palbociclib to endocrine therapy failed to improve invasive DFS among women with hormone receptor-positive, HER2-negative high-risk breast cancer, according to results of the phase 3 PENELOPE-B trial.
Adjuvant pertuzumab offers modest benefit for HER-2-positive breast cancer
CHICAGO — The addition of pertuzumab to adjuvant chemotherapy with trastuzumab demonstrated a significant, although modest, invasive DFS improvement for women with HER-2–positive breast cancer, according to results from the phase 3 APHINITY clinical trial presented at the ASCO Annual Meeting.
VIDEO: Trial demonstrates potential to move away from toxic chemotherapies for breast cancer
NEW ORLEANS — Angela DeMichele, MD, MSCE, professor of medicine and epidemiology at Perelman School of Medicine at University of Pennsylvania, presented results of the I-SPY 2 trial at the American Association for Cancer Research Annual Meeting.